<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50924">Sorafenib</z:chebi> is active in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute of Canada (NCIC) Clinical Trials Group initiated a phase I/II study of the combination of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in older patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who were unsuitable for intensive chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>FLT3 mutational status was determined in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-one patients were enrolled (four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 17 AML) with a median age of 77 years </plain></SENT>
<SENT sid="4" pm="."><plain>The recommended phase II dose (RP2D) was <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 10 mg bid days 1-10 and <z:chebi fb="0" ids="50924">sorafenib</z:chebi> 600 mg/day days 2-28 </plain></SENT>
<SENT sid="5" pm="."><plain>Dose-limiting toxicities were <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0100806'>sepsis</z:hpo> and <z:hpo ids='HP_0000988'>skin rash</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Of 15 evaluable patients treated at the RP2D, two patients responded </plain></SENT>
<SENT sid="7" pm="."><plain>The overall response rate for eligible patients was 10% </plain></SENT>
<SENT sid="8" pm="."><plain>FLT3 mutations were found in only three patients </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that this combination of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> has limited activity in this unselected cohort of elderly patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> in which FLT3 mutations seemed underrepresented </plain></SENT>
</text></document>